EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)
EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.
Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.
Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion Criteria:
Exclusion Criteria:
rebekah.taylor@abbvie.com(847) 937-8000
Ciudad Autonoma de Buenos Aire, Buenos Aires 1280, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D. 1426, Argentina
Córdoba, Córdoba Province 5016, Argentina
Buenos Aires, 1227, Argentina
Kingswood, New South Wales 2747, Australia
Sofiya, Sofia 1606, Bulgaria
Pleven, 5800, Bulgaria
Sofia, 1756, Bulgaria
St. John's, Newfoundland and Labrador A1B 3V6, Canada
Alexandroupoli, Evros 68100, Greece
Naples, Napoli 80131, Italy
Turin, Piedmont 10126, Italy
Rome, Roma 00133, Italy
Vila Real, 5000-185, Portugal
Santa Cruz de Tenerife, 38010, Spain
Cheltenham, Gloucestershire GL53 7AN, United Kingdom
+30 2613601130
+30 213 2061702
+30 213 2079100
+30 231 330 3110
+30 2313312672
+351259300500